Atea Pharmaceuticals Inc (AVIR)
3.73
-0.01
(-0.27%)
USD |
NASDAQ |
Apr 17, 16:00
3.73
0.00 (0.00%)
After-Hours: 20:00
Atea Pharmaceuticals Cash from Investing (TTM): 40.30M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 40.30M |
September 30, 2023 | 46.02M |
June 30, 2023 | -382.44M |
March 31, 2023 | -430.89M |
December 31, 2022 | -455.41M |
September 30, 2022 | -488.90M |
June 30, 2022 | -1.927M |
Date | Value |
---|---|
March 31, 2022 | -0.048M |
December 31, 2021 | -0.004M |
September 30, 2021 | -0.005M |
June 30, 2021 | -0.02M |
March 31, 2021 | -0.026M |
December 31, 2020 | -0.026M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-488.90M
Minimum
Sep 2022
46.02M
Maximum
Sep 2023
-128.72M
Average
-0.026M
Median
Dec 2020
Cash from Investing (TTM) Benchmarks
CEL-SCI Corp | -0.3835M |
AIM ImmunoTech Inc | -0.832M |
IGC Pharma Inc | -0.236M |
NovaBay Pharmaceuticals Inc | -0.019M |
Protalix BioTherapeutics Inc | -16.71M |